About Us

Gongwin adopts an innovative Tumor ablation therapy called MITTA therapy-“minimally-invasive targeted tumor ablation” for the treatment of focal malignancies. Our proprietary core technology is an intratumoral injection of our API-PTS (para-toluene sulfonamide) that is administered using existing diagnostic and minimally-invasive intervention techniques, which is unique and distinct way of treating focal malignancies in current market.

Our molecule has been newly listed in the pharmacopeia of China and has received marketing approval from NMPA (China) for treating Severe Malignant Airway Obstructions in Non-Small Cell Lung Carcinomas (NSCLC). In clinical studies, our product PTS 302 has successfully demonstrated its safety and Efficacy in treating tumors in airway obstructions and Gongwin Biopharm is confident to provide and introduce this therapeutic approach as a better novel treatment for treating focal malignancies in airways.

PTS intra tumoral injections have shown high selectivity for cancer cells and have minimum damage to healthy cells. It has also shown great results in treating tumors in H & N cancers, Liver cancer, breast cancer and other types. Clinical trials are currently being conducted in Taiwan, China & USA for following indications.

PTS 100 Hepatic Cellular Carcinoma (HCC) (Trials ongoing in Taiwan)

PTS 02 Tracheal Adeno Cystic Carcinoma (ODD status with USFDA)

PTS 500 Malignant Pleural Effusion (Trials ongoing in Taiwan)

GWB is also applying its core technology to develop formulas for ablating tumors in companion animals in Taiwan. Currently a field trials for treating Melanoma in Canines will start in Dec. 2022.

Gongwin Biopharm is also among the very few clinical stage biopharmaceutical companies in the world that is developing tumor ablating techniques for both Humans & for companion animals.